Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

The role of drug transporter polymorphisms in clinical practice (CROSBI ID 607460)

Prilog sa skupa u zborniku | izvorni znanstveni rad | međunarodna recenzija

Božina, Nada ; Lovrić, Mila ; Pejnović, Lana ; Mirošević Skvrce, Nikica The role of drug transporter polymorphisms in clinical practice // Arhiv za higijenu rada i toksikologiju 64(2) / Kopjar, Nevenka (ur.). Zagreb: Institut za medicinska istraživanja i medicinu rada, 2013. str. 342-342

Podaci o odgovornosti

Božina, Nada ; Lovrić, Mila ; Pejnović, Lana ; Mirošević Skvrce, Nikica

engleski

The role of drug transporter polymorphisms in clinical practice

Drug transporters play important role in carrying their substrates accross different barriers, and are an important factor of drug bioavailability. They can act as uptake or efflux transporters. Most efflux transporters belong to the ATP-binding cassette (ABC) superfamily of membrane proteins which may influence the intracellular concentration of numerous compounds in a variety of cells and tissues. They are expressed in the apical membranes of many barrier tissues such as the intestine, liver, blood-brain barrier, kidney, placenta, thus contributing to plasma and cerebrospinal fluid, but also to intracellular drug disposition. Of particular interest for drug dispositions are ABCB1 (for digoxin, HIV protease inhibitors, some antiepileptics, antidepressants, antipsychotics, immunosuppressants ; ABCC2 (anticancer drugs like methotrexate, cisplatin, irinotecan, antibiotics), ABCG2 (anticancer drugs, fluvastatin, cimetidin). Variability in their expression and activity due to genetic polymorphisms can cause treatment failures and adverse drug reactions. The main uptake carrier systems are organic anion transporters (OATP). OATP1B1 (coded by SLCO1B1 gene) is a polymorphic influx transporter expressed on the sinusoidal membrane of human hepatocytes where it mediates the hepatic uptake of different endogenous compounds and xenobiotics. A common SNP c.521T>C in the SLCO1B1 decreases the transporting activity of OATP1B1, resulting in increased plasma concentrations of drug-substrates like statins. This polymorphism enhances the risk of statin- induced myopathy and even of rhabdomyolysis. Some SLCO1B1 variants can also influence the clearence of methotrexate, and increase the risk of gastrointestinal toxicity. Among other drugs recognized as OATP1B1 substrates are mycophenolic acid, sirolimus, valsartan, enalapril, torsemide, rifampin, cephalosporins, HIV protease inhibitors, methotrexate and irinotecan.

genetic polymorphism; drug bioavailability; apical membrane; adverse drug reactions; organic anion transporters; multidrug- resistant proteins

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

342-342.

2013.

objavljeno

Podaci o matičnoj publikaciji

Arhiv za higijenu rada i toksikologiju 64(2)

Kopjar, Nevenka

Zagreb: Institut za medicinska istraživanja i medicinu rada

Podaci o skupu

1. hrvatski simpozij o transporterima SOT-1

pozvano predavanje

06.06.2013-07.06.2013

Zagreb, Hrvatska

Povezanost rada

Kliničke medicinske znanosti

Poveznice